Wake up: Modern Strategies to Recognize and Combat Sleepiness in Narcolepsy and Idiopathic Hypersomnia - An Adaptation of a Virtual Grand Rounds Series (Credit Expired)

Program Description

Estimated to occur in up to a third of the general population with 25 or so different causes, excessive daytime sleepiness (EDS) can be difficult to trace back to its root cause. Some of the more prevalent disorders associated with this symptom include narcolepsy type 1 (NT-1), narcolepsy type 2 (NT-2), and idiopathic hypersomnia (IH). However, the lines between these disorders have been mobile and debated for years which has made their recognition and management challenging for treating clinicians. In the midst of these discussions, several new therapies have also emerged in this realm with important considerations that may impact individual patients differently. Complicating matters further, IH, previously lacking in FDA-approved options entirely, received its first indicated agent just this past year, breaking the mold of how clinicians have been approaching IH for decades.

To assist clinicians in navigating these difficult-to-treat populations, this program reviews the self-reported management approaches of five renowned sleep specialists and the underlying research data that support those decisions.

Target Audience

The target audience for this CME initiative includes general neurologists, sleep specialists, advanced practice professionals, and other sleep clinicians involved in the diagnosis and long-term management of patients with varying sleep disorders.

Learning Objectives

  1. Examine clinical characteristics and variable diagnostic considerations of narcolepsy type 1 (NT-1), narcolepsy type 2 (NT-2), and idiopathic hypersomnia (IH) to improve condition differentiation and timely diagnosis.
  2. Identify the biologic mechanism underlying the overlapping effectiveness of traditional and low sodium oxybate in patients with NT1-, NT2-, and IH-associated EDS, and use this information to identify individuals that may be appropriate candidates for their use.
  3. Compare the patient selection for and clinical profiles of traditional (e.g., modafinil, SSRIs) and recently approved (e.g., pitolisant, solriamfetol, low sodium oxybate) agents for EDS secondary to narcolepsy and/or IH to discern how and for whom these agents can be effectively and safely prescribed.
Course summary
Course opens: 
05/17/2022
Course expires: 
05/17/2025
Cost:
$0.00
Rating: 
0

Faculty (Roundtable Panelists)

   Phyllis Zee, MD, PhD
   Director, Center for Circadian and Sleep Medicine
   Chief, Division of Sleep Medicine
   Feinberg School of Medicine
   Northwestern University
   Chicago, IL

 

   Asim Roy, MD
   Medical Director
   Ohio Sleep Medicine Institute
   Clinical Assistant Professor
   Northeast Ohio Medical University
   Dublin, OH

 

Other Grand Rounds Project Steering Committee Members

   Russell Rosenberg, PhD, D.ABSM (Chair)
   Founder & Director
   Atlanta School of Sleep Medicine and Technology
   Director & CEO
   NeuroTrials Research, Inc
   Atlanta, GA

 

   Clete Kushida, MD, PhD, FASSM
   Professor of Psychiatry and Behavioral Sciences
   Stanford University
   Palo Alto, CA


 

 

   Heidi Riney, MD, D.ABPN
   Medical Director
   Neurologist
   Fusion Sleep Center
   Atlanta, GA
 

 

   Michael Thorpy, MD
   Director, Sleep-Wake Disorders Center
   Montefiore Medical Center
   Professor of Neurology
   Albert Einstein College of Medicine
   Bronx, NY

Credit for this program has expired. The accreditation information below is based on the activity release date.

This activity is jointly provided by Postgraduate Institute for Medicine and Efficient LLC. 

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

PIM designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflict of Interest

Disclosures

PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure

PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Faculty Disclosures

Dr. Kushida reported the following financial relationships:

  • Consulting Fees: Avadel Pharmaceuticals (Avadel), Jazz Pharmaceuticals (Jazz), XW Pharma

Dr. Rosenberg reported the following financial relationships:

  • Consulting Fees: Harmony Biosciences (Harmony), Jazz, Takeda
  • Contracted Research: Eisai Co. Ltd. (Eisai), Jazz, Suven Life Sciences (Suven), Takeda

Dr. Roy reported the following financial relationships:

  • Consulting Fees: Avadel, Harmony, Inspire Pharmaceuticals (Inspire), Jazz
  • Fees for Non-CE Services: Eisai, Harmony, Inspire, Jazz
  • Contracted Research: Avadel, Eisai, Harmony, Inspire, Jazz, LiveNova, Nyxoah

Dr. Thorpy reported the following financial relationships:

  • Consultant/Advisory Board: Avadel, Axsome Therapeutics, Balance Therapeutics, Eisai, Harmony, Jazz, NLS Pharmaceuticals, Suven, Takeda, XW Pharma

Dr. Zee reported the following financial relationships:

  • Royalty: Wolter-Kluwer
  • Consulting Fees: Eisai, Harmony, Itamar Medical Ltd., Jazz, Takeda
  • Contracted Research: Philips, Vanda Pharmaceuticals
  • Ownership Interest: Teva Pharmaceuticals

Dr. Riney reported no relevant financial relationships.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Commercial Support

This activity is supported by educational grants from Jazz Pharmaceuticals.

Price

Cost:
$0.00
Please login or register to take this course.